Clidinium

CHEMBL620 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

352.4 g/mol

LogP

3.3

Phase

4

An anticholinergic agent that reduces stomach acid secretion and relieves gastrointestinal muscle spasms by blocking muscarinic receptors. It is often combined with a benzodiazepine to treat irritable bowel syndrome and peptic ulcers.

الوزن الجزيئي

352,4000 g/mol

LogP

3,30

TPSA

46,50 Å²

قاعدة ليبينسكي للخمسة

ناجح

آلية العمل

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2

InChI

InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1

Molecular Formula

C22H26NO3+

HBD / HBA

1 / 3

الروابط القابلة للدوران

5

الذرات الثقيلة

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An anticholinergic agent that reduces stomach acid secretion and relieves gastrointestinal muscle spasms by blocking muscarinic receptors. It is often combined with a benzodiazepine to treat irritable bowel syndrome and peptic ulcers.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Clidinium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL620. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2784. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Clidinium على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C22H26NO3+
المرادفات: 4

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.